ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL)
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TO THE EDITOR
The translocation t(9;22) is present in 3 to 5% of children with acute lymphoblastic leukemia (ALL) and in less than 1% of children with acute myeloid leukemia (AML). Besides ALL and AML, there is a rare third subtype of acute leukemias, AMLL, defined as immunologically biphenotypic leukemia, leukemia with morphological evidence of two distinct blast populations or with lineage switch. [1] [2] [3] While accounting for less than 1% of all leukemias in German children, AMLL has a Philadelphia chromosome-positive (Ph+) rate of 10% in the Berlin-Frankfurt-Mü nster (BFM)-AML trials, 3 the highest rate among all pediatric acute leukemias.
Ph+ acute leukemias have a markedly poorer prognosis than most other acute leukemias in children. 4 This is especially true for the rare AMLL. 5 One major problem is the significantly lower complete remission (CR) rate of Ph+ acute leukemias which is the first prerequisite for successful therapy.
Out of seven children with Ph+ AMLL enrolled in the BFM-AML studies since 1987 (total 1683 patients), only four achieved CR. Six children died from refractory or relapsed leukemia within 0.23 to 1.88 years (median 0.88 years). At diagnosis they were characterized by unfavorable features such as a higher average age (10.7 years) and a significantly higher initial WBC (319 000/l) in comparison to other AMLL as well as AML and ALL.
Early trials in adults suggest that imatinib can be an effective agent in refractory or relapsed Ph+ ALL and AML. 6 inhibits ABL tyrosine kinase, which is constitutively activated in Ph+ leukemias. We treated a 12-year-old boy with acute biphenotypic leukemia (expression of CD7, CD10, CD19, CD22, cytCD79a, CD13, CD33, CD34, and partially CD15) 1,2 initially presenting with hyperleukocytosis of 130 000/l. The leukemic blasts showed an abnormal karyotype of 45,XY,−7,t(9;22)(q34;q11),t(16;19)(q11;p13). The minor-BCR (m-BCR)/ABL fusion transcripts were detected by reverse-transcription polymerase chain reaction (RT-PCR).
ALL-and AML-directed therapy (prednisolone, thioguanine, Ara-C, idarubicin, VP 16) failed to bring about hematological remission, with a blast persistence in bone marrow above 50%. As a consequence of chemotherapy, the boy suffered from persisting neutropenic fever of unknown origin as well as a grade 4 mucositis. Therefore, we decided to treat with imatinib starting 14 days after chemotherapy. The patient, at a body weight of 30 kg, received imatinib 500 mg per day during the initial 14 days and 300 mg per day during 2 subsequent days. Because of persisting neutropenia, we interrupted imatinib administration after 16 days. Four weeks after the beginning of imatinib therapy, we initiated a further intensive conventional chemotherapy (highdose Ara-C, mitoxantrone) in view of the risk of an early successive relapse after imatinib monotherapy. 6 Subsequently, the patient underwent allogeneic bone marrow transplantation (BMT) from an unrelated donor.
Evaluation of response was carried out by cytology of peripheral blood and bone marrow, by four-color immunophenotyping and flow cytometric detection of minimal residual disease (MRD) and by realtime quantitative RT-PCR (RQ-RT-PCR) analysis of the ratio m-BCR-ABL/ABL (%) with TaqMan Universal PCR Master Mix.
Ten, 14, 21 and 27 days after starting imatinib, bone marrow cytology displayed a decrease of blast count to under 5% of total cellularity. There were no residual blasts in the peripheral blood. The bone marrow cellularity started to improve at day 21, but still remained hypoplastic until day 27. However, at this time hematological reconstitution was visible with a platelet count of more than
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Figure 1
Cytological, flow cytometric and RQ-RT-PCR monitoring of response in a pediatric Ph+ AMLL treated with chemotherapy and imatinib. Course of response in bone marrow cytology (a), in flow cytometry represented by CD34/CD19 + blast population (b) and in quantitative RT-PCR analysis of the ratio m-BCR-ABL/ABL (%) (c) at the time of diagnosis (left), 2 weeks after AIE (Ara-C, idarubicin, VP 16) (middle) and 4 weeks after starting imatinib (right). Cytology and flow cytometry showed a blast content in the bone marrow of 50-80% after AIE and a content less than 5% after imatinib. The ratio m-BCR-ABL/ABL decreased from 66.2% at the time of diagnosis (left red triangle), to 31.6% 3 weeks and to 42.1% 4 weeks after chemotherapy start (middle red triangle) and to 7.1% 4 weeks after therapy with imatinib (right red triangle).
Figure 2
Complete hematological response after imatinib in a child suffering from chemotherapy refractory Ph+ AMLL. Course of leukemic blasts (in % of the nucleated cells) in the bone marrow (í), leukemic blast count in the peripheral blood (/nl) (᭜) and absolute neutrophil count (/nl ×100) ( ) under treatment with prephase therapy (prednisolone, thioguanine, Ara-C) and AIE (Ara-C, idarubicin, VP 16), imatinib and HAM (high-dose Ara-C, mitoxantrone). 100 000/l and an absolute neutrophil count of 350/l in the peripheral blood. Flow cytometric MRD analysis confirmed the morphological remission at days 14, 21 and 27 with detection of 2-3% residual blasts in the bone marrow. RQ-RT-PCR analysis of the ratio m-BCR-ABL/ABL showed a decline from 42.1% m-BCR-ABL/ABL, prior to imatinib administration, to 9.1, 7.6, 7.3 and 7.1% at day 10, 14, 21 and 27 after starting imatinib, respectively (Figure 1) .
Eight weeks after starting imatinib, ie 4 weeks after conventional chemotherapy following imatinib, CR was achieved with a peripheral neutrophil count above 1500/l and a platelet count above 100 000/l (Figure 2) . A marrow blast reduction by a factor of 10, to approximately 0.3%, was detected by flow cytometric analysis. Furthermore, the RQ-RT-PCR analysis showed a 20-fold decrease in the ratio m-BCR-ABL/ABL to 0.4%.
Toxicity observed during imatinib therapy was limited to nausea and vomiting (grade 2) as well as neutropenia and thrombocytopenia (maximal grade 4 according to the Common Toxicity Criteria of the National Cancer Institute 7 ), which persisted for 2 weeks after the end of imatinib administration.
One hundred days after BMT, the patient still demonstrates complete hematological as well as molecular remission (0% m-BCR-ABL/ABL). To our knowledge, this is the first report of effective salvage therapy with imatinib of childhood Ph+ acute leukemia refractory to standard chemotherapy. Prospective clinical studies are needed in order to assess the value of imatinib when combined with established chemotherapy protocols. 
